BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 23871496)

  • 1. Body adiposity but not insulin resistance is associated with -675 4G/5G polymorphism in the PAI-1 gene in a sample of Mexican children.
    de la Cruz-Mosso U; Muñoz-Valle JF; Salgado-Bernabé AB; Castro-Alarcón N; Salgado-Goytia L; Sánchez-Corona J; Flores-Martínez SE; Parra-Rojas I
    J Pediatr (Rio J); 2013; 89(5):492-8. PubMed ID: 23871496
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of plasminogen activator inhibitor-1 gene 4G/5G polymorphism on glucose and lipid metabolisms in Turkish obese children.
    Kinik ST; Ataç FB; Verdi H; Cetintaş S; Sahin FI; Ozbek N
    Clin Endocrinol (Oxf); 2005 May; 62(5):607-10. PubMed ID: 15853833
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PAI-1 gene 4G/5G polymorphism, cytokine levels and their relations with metabolic parameters in obese children.
    Kinik ST; Ozbek N; Yuce M; Yazici AC; Verdi H; Ataç FB
    Thromb Haemost; 2008 Feb; 99(2):352-6. PubMed ID: 18278185
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasminogen activator inhibitor-1 (PAI-1) gene polymorphism (-675 4G/5G) associated with obesity and vascular risk in children.
    Berberoğlu M; Evliyaoğlu O; Adiyaman P; Ocal G; Ulukol B; Simşek F; Siklar Z; Törel A; Ozel D; Akar N
    J Pediatr Endocrinol Metab; 2006 May; 19(5):741-8. PubMed ID: 16789641
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of the 4G/5G polymorphism of PaI-1 gene promoter on PaI-1 levels in obese patients: influence of fat distribution and insulin-resistance.
    Sartori MT; Vettor R; De Pergola G; De Mitrio V; Saggiorato G; Della Mea P; Patrassi GM; Lombardi AM; Fabris R; Girolami A
    Thromb Haemost; 2001 Nov; 86(5):1161-9. PubMed ID: 11816701
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association analysis of the plasminogen activator inhibitor-1 4G/5G polymorphism in Hispanics and African Americans: the IRAS family study.
    Bensen JT; Hsu FC; Brown WM; Sutton BS; Norris JM; Tracy RP; Jenny NS; Saad MF; Haffner S; Bowden DW; Langefeld CD
    Hum Hered; 2004; 57(3):128-37. PubMed ID: 15297806
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Promoter (4G/5G) plasminogen activator inhibitor-1 genotype and plasminogen activator inhibitor-1 levels in blacks, Hispanics, and non-Hispanic whites: the Insulin Resistance Atherosclerosis Study.
    Festa A; D'Agostino R; Rich SS; Jenny NS; Tracy RP; Haffner SM
    Circulation; 2003 May; 107(19):2422-7. PubMed ID: 12719278
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Insulin resistance after precocious pubarche: relation to PAI-1-675 4G/5G polymorphism, and opposing influences of prenatal and postnatal weight gain.
    López-Bermejo A; Casano-Sancho P; Petry CJ; Jaramillo AM; Rodríguez-González FX; Dunger DB; de Zegher F; Ibáñez L
    Clin Endocrinol (Oxf); 2007 Oct; 67(4):493-9. PubMed ID: 17555513
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The plasminogen activator inhibitor-1 (PAI-1) gene -844 A/G and -675 4G/5G promoter polymorphism significantly influences plasma PAI-1 levels in women with polycystic ovary syndrome.
    Lin S; Huiya Z; Bo L; Wei W; Yongmei G
    Endocrine; 2009 Dec; 36(3):503-9. PubMed ID: 19856137
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of -675 4G/5G in the plasminogen activator inhibitor-1 gene and -308G/A tumor necrosis factor-α gene polymorphisms in obese Argentinean patients.
    Wingeyer SD; Graffigna MN; Belli SH; Benetucci J; de Larrañaga GF
    Genet Test Mol Biomarkers; 2012 May; 16(5):372-5. PubMed ID: 22106856
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The prevalence of 4G5G polymorphism of plasminogen activator inhibitor-1 (PAI-1) gene in polycystic ovarian syndrome and its association with plasma PAI-1 levels.
    Diamanti-Kandarakis E; Palioniko G; Alexandraki K; Bergiele A; Koutsouba T; Bartzis M
    Eur J Endocrinol; 2004 Jun; 150(6):793-8. PubMed ID: 15191349
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The -675 4G/5G
    Anaya-Macias BU; De la Cruz-Mosso U; Palafox-Sánchez CA; Parra-Rojas I; Martínez-Bonilla G; González-López L; Gámez-Nava JI; Pérez-Guerrero EE; Barrientos-Avalos SL; Muñoz-Valle JF
    Autoimmunity; 2020 Mar; 53(2):71-77. PubMed ID: 31829037
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is the plasminogen activator inhibitor-1 gene a candidate gene predisposing to hypertension? Results from a population-based study in Spain.
    Martínez-Calatrava MJ; González-Sánchez JL; Zabena C; Martínez-Larrad MT; Luque-Otero M; Serrano-Ríos M
    J Hypertens; 2007 Apr; 25(4):773-7. PubMed ID: 17351368
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association between the -844 G>A, HindIII C>G, and 4G/5G
    Valdés-Alvarado E; Huerta M; Trujillo X; Valle Y; Padilla Gutiérrez JR; Mireles-Ramírez MA; Macías-Islas MA; Luz Margarita BR; Muñoz-Valle JF
    Dis Markers; 2019; 2019():9626289. PubMed ID: 31687051
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma PAI-1 levels in obese children--effect of weight loss and influence of PAI-1 promoter 4G/5G genotype.
    Estellés A; Dalmau J; Falcó C; Berbel O; Castelló R; España F; Aznar J
    Thromb Haemost; 2001 Aug; 86(2):647-52. PubMed ID: 11522017
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PAI-1 Gene 4G/5G polymorphism and risk of type 2 diabetes in a population-based sample.
    Meigs JB; Dupuis J; Liu C; O'Donnell CJ; Fox CS; Kathiresan S; Gabriel SB; Larson MG; Yang Q; Herbert AG; Wilson PW; Feng D; Tofler GH; Cupples LA
    Obesity (Silver Spring); 2006 May; 14(5):753-8. PubMed ID: 16855181
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The 4G/5G polymorphism of the plasminogen activator inhibitor gene is associated with the time course of progression to acute coronary syndromes.
    Iwai N; Shimoike H; Nakamura Y; Tamaki S; Kinoshita M
    Atherosclerosis; 1998 Jan; 136(1):109-14. PubMed ID: 9544737
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of PAI-1 4G/5G and -844G/A gene polymorphism and changes in PAI-1/tPA levels in stroke: a case-control study.
    Saidi S; Slamia LB; Mahjoub T; Ammou SB; Almawi WY
    J Stroke Cerebrovasc Dis; 2007; 16(4):153-9. PubMed ID: 17689411
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of PAI-1 4G/5G and -844G/A gene polymorphisms and changes in PAI-1/tissue plasminogen activator levels in myocardial infarction: a case-control study.
    Abboud N; Ghazouani L; Saidi S; Ben-Hadj-Khalifa S; Addad F; Almawi WY; Mahjoub T
    Genet Test Mol Biomarkers; 2010 Feb; 14(1):23-7. PubMed ID: 19929406
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasminogen activator inhibitor I 4G/5G polymorphism in neonatal respiratory distress syndrome.
    Armangil D; Yurdakök M; Okur H; Gürgey A
    Clin Appl Thromb Hemost; 2011 Aug; 17(4):352-7. PubMed ID: 20460339
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.